A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)

Change in body weight

Measured in kilograms (kg).

Time frame: From baseline (week 0) to end of follow-up (week 30+- 4 weeks)

Change in body weight

Measured as percentage (%).

Time frame: From baseline (week 0) to end of follow-up (week 30+- 4 weeks)

Change in waist circumference

Measured in centimeter (cm).

Time frame: From baseline (week 0) to end of follow-up (week 30+- 4 weeks)

Change in fasting plasma glucose (FPG)

Measured in millimoles per liter (mmol/l).

Time frame: From baseline (week 0) to end of follow-up (week 30+- 4 weeks)

Change in Lipid parameters (total cholesterol, low density lipoprotein cholesterol [LDLc], high density lipoprotein cholesterol [HDLc], triglycerides)

Measured in millimoles per liter (mmol/L).

Time frame: From baseline (week 0) to end of follow-up (week 30+- 4 weeks)

Change in Blood Pressure (systolic and diastolic)

Measured in millimiters of mercury (mmHg).

Time frame: From baseline (week 0) to end of follow-up (week 30+- 4 weeks)

Glycated haemoglobin (HbA1c) less than 7%

Measured as Yes/No.

Time frame: At end of follow-up (week 30 +- 4 weeks)

Reduction in glycated haemoglobin (HbA1c) greater than or equal to (>=) 1%

Measured as Yes/No.

Time frame: From baseline (week 0) to end of follow-up (week 30+- 4 weeks)

Weight loss >= 5%

Measured as Yes/No.

Time frame: From baseline (week 0) to end of follow-up (week 30+- 4 weeks)

Weight loss >= 3%

Measured as Yes/No.

Time frame: From baseline (week 0) to end of follow-up (week 30+- 4 weeks)

HbA1c reduction >= 1% and weight loss of >=3%

Measured as Yes/No.

Time frame: From baseline (week 0) to end of follow-up (week 30+- 4 weeks)

Having at least 1 severe hypoglycaemic episode

Measured as Yes/No.

Time frame: At end of follow-up (week 30 +- 4 weeks)